성균관대학교 화학공학과 학사 (1997)
광주과학기술원 신소재공학과 석사 (1999)
광주과학기술원 신소재공학과 박사 (2003)

(2003.08 - 2005.07) 한국과학기술연구원 박사 후 연구원
(2005.08 - 2011.02) 한국과학기술연구원 선임연구원
(2011.03 - 2022.08) 한국과학기술연구원 책임연구원
(2017.03 - 2022.08) 고려대학교, KU-KIST 융합대학원 학연교수
(2022.09 - 현재) 이화여자대학교 약학대학 석좌교수

- 자가조립형 펩타이드 및 리포좀 기반 항암제 나노입자 개발 및 평가
- 나노입자 및 면역관문억제제 병용 투여 치료 효능 평가
- 나노입자 구성 요소 및 항암제 다각화를 통한 환자 맞춤형 치료법 모색

Implantable MicroLED‐Mediated Chemo‐Photodynamic Combination Therapy for Glioma Treatment, Advanced Functional Materials, 2024, 34, 2316386
All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy, Bioactive Materials, 2023, 28, 358
In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy, Biomaterials, 2023, 295, 122038
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity, Biomaterials, 2022, 290, 121841
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death, Theranostics, 2022, 12(5), 1999
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis, Biomaterials, 2021, 279, 121189
Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy, ACS Nano, 2021, 15(7), 12086
Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy, Biomaterials, 2020, 261, 120347

● HPLC

● LC-MS

● IVIS

● FACS

● EVOS

항암제, 약물전달, 카텝신-B, 면역치료, 나노입자